Literature DB >> 3894247

SQM1 antibody defines a surface membrane antigen in squamous carcinoma of the head and neck.

K Boeheim, J A Speak, E Frei, S D Bernal.   

Abstract

We produced murine monoclonal antibodies (MAbs) directed against the surface membrane of squamous-cell carcinoma of the head and neck (SCCHN). One antibody, SQM1, was determined by immunofluorescence and radioimmunoassay to be reactive with 13/13 SCCHN cell lines derived from different sites of the head and neck area. No binding reaction was observed with normal fibroblasts, red blood cells, nucleated bone-marrow cells or epithelial cells from normal oral mucosa. SQM1 reactivity was observed with primary cultures of normal epidermal and bronchial epithelial cells. Significant reactivity was found with 2/4 cell lines derived from small-cell carcinoma of the lung but little or no reactivity was found with other lung cancer cell lines. Various cell lines derived from other cancers including breast, colon, and ovarian carcinomas, melanoma, neuroblastoma and leukemia were generally unreactive. Seventeen out of 18 fresh frozen specimens of SCCHN were strongly reactive with SQM1 antibody. However, autopsy specimens from the heart, liver, kidney, spleen, colon, subcutaneous fat and skin connective tissue were unreactive. SQM1 antibody may be useful in biological and clinical studies of the head and neck region.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3894247     DOI: 10.1002/ijc.2910360203

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum.

Authors:  S D Bernal; J A Speak; K Boeheim; A I Dreyfuss; J E Wright; B A Teicher; A Rosowsky; S W Tsao; Y C Wong
Journal:  Mol Cell Biochem       Date:  1990-06-01       Impact factor: 3.396

Review 2.  [Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy].

Authors:  T K Hoffmann; T L Whiteside; H Bier
Journal:  HNO       Date:  2005-03       Impact factor: 1.284

3.  Potential for targeting head and neck squamous cell carcinoma with monoclonal antibody K984.

Authors:  A H Schrijvers; M Gerretsen; M van Walsum; B J Braakhuis; J J Quak; G B Snow; G A van Dongen
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma.

Authors:  H Bier; K A Reiffen; I Haas; P Stasiecki
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

5.  Production and characterisation of a monoclonal antibody (Cx-99) against cervical carcinoma.

Authors:  C C Yuan; L C Tsai; S C Hsu; H T Ng; S J Tsai; H M Chen; M W Hung; C K Ho; D M Ho; T J Gill
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

6.  Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.

Authors:  M Gerretsen; J J Quak; J S Suh; M van Walsum; C J Meijer; G B Snow; G A van Dongen
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.